Turn Therapeutics Inc. (TTRX)
| Market Cap | 208.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.56M |
| Shares Out | 28.02M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,397,265 |
| Open | 8.25 |
| Previous Close | 9.20 |
| Day's Range | 7.25 - 8.80 |
| 52-Week Range | 6.23 - 26.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Tu... [Read more]
News
U.S. IPO Weekly Recap: 6 IPOs Debut, Pipeline Grows, Despite Government Shutdown
Six IPOs debuted this week, while two SPACs listed. Thirteen IPOs and five SPACs also submitted initial filings. No traditional IPOs are currently scheduled for the week ahead as the government shutdo...
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing dermatology, wound care, and anti-infective therapies, today a...